- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Total R&D costs including costs of capital for select cancer drugs 2017
Total R&D costs including costs of capital for select cancer drugs 2017
Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
Loading statistic...
| Drug name (company, R&D start date) | Cost in million U.S. dollars |
|---|---|
| Cabozantinib (Exelixis, 01/2004) | 2,601.7 |
| Ruxolitinib (Incyte Corp., 01/2004) | 1,374.3 |
| Brentuximab vedotin (Seattle Genetics, 01/2001) | 1,119.2 |
| Eculizumab (Alexion Pharm., 01/1992)* | 1,088 |
| Irinotecan liposome (Merrimack Pharm., 12/2009)** | 959.8 |
| Enzalutamide (Medivation, 08/2005)** | 554.9 |
| Ponatinib (Ariad Pharm., 01/2007) | 548.4 |
| Ibrutinib (Pharmacyclics, 04/2006)** | 388.7 |
| Pralatrexate (Allos Therap., 12/2002)** | 217.4 |
| Vincristine liposome (Talon Therap., 05/2006)** | 203.6 |
| Drug name (company, R&D start date) | Cost in million U.S. dollars |
|---|---|
| Cabozantinib (Exelixis, 01/2004) | 2,601.7 |
| Ruxolitinib (Incyte Corp., 01/2004) | 1,374.3 |
| Brentuximab vedotin (Seattle Genetics, 01/2001) | 1,119.2 |
| Eculizumab (Alexion Pharm., 01/1992)* | 1,088 |
| Irinotecan liposome (Merrimack Pharm., 12/2009)** | 959.8 |
| Enzalutamide (Medivation, 08/2005)** | 554.9 |
| Ponatinib (Ariad Pharm., 01/2007) | 548.4 |
| Ibrutinib (Pharmacyclics, 04/2006)** | 388.7 |
| Pralatrexate (Allos Therap., 12/2002)** | 217.4 |
| Vincristine liposome (Talon Therap., 05/2006)** | 203.6 |
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Show more- Show sources information
- Show publisher information
- Release date
- November 2017
- Region
- United States
- Survey time period
- as of November 2017
- Supplementary notes
-
This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.
Source
- Show sources information
- Show publisher information
- Release date
- November 2017
More information
- Region
- United States
- Survey time period
- as of November 2017
- Supplementary notes
-
This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista is a great source of knowledge, and pretty helpful to manage the daily work.Christof Baron
CEO, MindShare Germany
Statistics on "Oncology"
- Cancer facts
The most important statistics
- Leading causes of death worldwide in 2016 (in millions)Global death rate - leading causes 2016
- Number of cancer deaths worldwide in 2016, by major type of cancerCancer deaths worldwide by major type 2016
- Number of U.S. Americans with a history of cancer living between 2004 and 2016 (in millions)U.S. Americans with a history of cancer living 2004-2016
- Number of new cancer cases in the United States from 1999 to 2015*Number of new cancer cases in U.S. from 1999 to 2015
- Deaths by cancer in the U.S. from 1950 to 2016 (per 100,000 population)*Deaths by cancer in the U.S. 1950-2016
- Oncology market
The most important statistics
- Global oncology spending from 2010 to 2017 (in billion U.S. dollars)*Global oncology costs 2010-2017
- Projected growth and spending in oncology market globally from 2012 to 2022 (in billion U.S. dollars)Expenditure and growth worldwide in oncology market 2012-2022
- Global oncology therapeutic medicine spending in the period 2013-2017, by regionOncology medicine spending growth 2013-2017, by region
- Projected global oncology spending in 2022, by region (in billion U.S. dollars)Predicted oncology spending in 2022, by region
- Emerging cancer diagnostics market size worldwide in 2015 and 2023, by region (in billion U.S. dollars)Emerging cancer diagnostics market size by world region 2015 and 2023
- Growth of the U.S. oncology therapeutic market from 2012 to 2017, by segment (in billion U.S. dollars)Oncology therapeutic market growth U.S. 2012-2017, by segment
- Companies
The most important statistics
- Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024 (in million U.S. dollars)Global oncology revenue by top ten pharmaceutical companies 2017 and 2024
- Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024Global top pharmaceutical companies by oncology market share 2017 and 2024
- Revenue distribution of Roche's Pharmaceuticals division in 2017 and 2018, by therapeutic areaRevenue share of Roche's Pharmaceuticals division by therapy area 2017-2018
- Revenues of biotech company Celgene's top products from 2013 to 2018 (in million U.S. dollars)Celgene's top product revenues 2013-2018
- Bristol-Myers Squibb's top products based on revenue from 2015 to 2018 (in million U.S. dollars)Bristol-Myers Squibb's top products based on revenue 2015-2018
- Venture investments in oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)U.S. venture investments in oncology companies 2006-2017
- Amount raised through initial public offerings (IPOs) from oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)*U.S. oncology company IPO money raised 2006-2017
- Cancer drugs
The most important statistics
- Top 5 oncology products worldwide based on revenue in 2017 and 2024 (in million U.S. dollars)*Top 5 worldwide oncology products by revenue 2017 and 2024
- Top 5 oncology products worldwide by market share in 2017 and 2024Top 5 worldwide oncology products by market share 2017 and 2024
- Availability of new cancer drugs launched in 2012-2016 in selected countries as of 2017Availability of new cancer drugs by country as of 2017
- Leading U.S. oncology brands based on revenue in 2016 (in million U.S. dollars)Top U.S. oncology products by revenue in 2016
- Number of oncology drugs by treatment cost and number of patients in the U.S. as of 2017Number of cancer drugs by cost and number of patients U.S. 2017
- Research and development
The most important statistics
- Distribution of FDA breakthrough therapy requests by therapy area in 2018FDA on breakthrough therapy requests by therapy area 2018
- Distribution of FDA breakthrough therapy requests granted by therapy area in 2018FDA on breakthrough therapy requests granted by therapy area 2018
- Distribution of late phase oncology pipeline in 2007 and 2017, by typeDistribution of late phase oncology pipeline in 2017 by type
- Number of cancer drugs in development in the United States in select years between 2005 and 2018Number of cancer drugs in development in the U.S. 2005-2018
- Time between R&D start and approval of selected cancer drugs on the market as of 2017 (in years) Time from R&D start to approval of select cancer drugs 2017
- Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)Total R&D costs including costs of capital for select cancer drugs 2017
- Immuno-oncology
The most important statistics
- Top 10 mechanisms of action in R&D pipeline drugs worldwide by number of active compounds in 2019*Worldwide top drug producing mechanisms of action by number of active compounds 2019
- Distribution of the immuno-oncology pipeline worldwide as of 2018, by mechanism of actionDistribution of the immuno-oncology pipeline worldwide 2018, by mechanism of action
- Global cancer immunotherapy market in 2016 and projection for 2022 (in billion U.S. dollars)Global cancer immunotherapy market size 2016 and 2022 forecast
- Market share forecast for top immuno-oncology companies worldwide in 2021*Global cancer immunotherapy sales share by type 2021 forecast
- Top 10 immuno-oncology collaborations worldwide based on value as of 2018 (in billion U.S. dollars)Leading cancer immunotherapy collaborations worldwide by value 2018
- Treatment types
The most important statistics
- Distribution of treatment types for female breast cancer in the U.S. in 2013, by stageDistribution of treatment types for female breast cancer by stage 2013
- Distribution of treatment types for prostate cancer in the U.S. in 2010-2012Distribution of treatment types for prostate cancer 2010-2012
- Distribution of treatment types for colon cancer in the U.S. in 2013, by stageDistribution of treatment types for colon cancer by stage 2013
- Distribution of treatment types for lung cancer in the U.S. in 2013*Distribution of treatment types for lung cancer in the U.S. 2013
- Distribution of treatment types for non-Hodgkin lymphoma in the U.S. in 2013Distribution of treatment types for non-Hodgkin lymphoma 2013
- Physicians and patients
The most important statistics
- Number of oncologists per one million people in select countries as of 2018Number of oncologists per one million people by select country 2018
- Number of active physicians in the U.S. in 2018, by specialty areaNumber of active physicians in the U.S. 2018 by specialty area
- Hours per week that oncologists in the U.S. spend seeing patients as of 2018Number of hours U.S. oncologists spend a week seeing patients 2018
- Minutes that oncologists in the U.S. spend with each patient as of 2018Number of minutes U.S. oncologists spend with each patient 2018
- Medication usage among patients with cancer in selected countries as of 2018*Cancer patients using medication in select countries 2018
- Lifestyle among patients with cancer in selected countries as of 2018*Cancer sufferers based on lifestyle habits by select country 2018
- Average length of stay in U.S. hospitals per inpatient cancer cases from 2008 to 2016 (in days)Inpatient average length of stay in U.S. hospitals by cancer type 2008-2016
- Percentage of patients whose tumors are driven by certain genetic mutations as of 2016, by cancer typePatients whose tumors are driven by genetic mutations by cancer type 2016
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Revenue as a part of R&D spending for select cancer drugs 2017
- Revenue since approval for select cancer drugs 2017
- Unsuccessful developing lung cancer drugs in the U.S. 1998-2014
- USA: Active ingredients in anti-cancer drugs 2004-2013
- Unsuccessful developing melanoma drugs in the U.S. 1998-2014
- Average prices of Gleevec - selected countries 2013
- Italy: consumption of cancer drugs 2017, by region
- Unsuccessful developing brain cancer drugs in the U.S. 1998-2014
- Proportion of cancer drugs on the world pharmaceutical market
- Number of new cancer pharmaceuticals approved by EMA in Sweden 2014-2017
- U.S. average invoice price increase for oncology brands 2012-2017
- Italy: number of clinical trials 2017, by type of drug
- Metastatic cancer treatment market worldwide 2017 and 2025
- Top cancer drugs paid by Medicare Part B by sales price per dosage 2014
- Expensive cancer drugs by annual Medicare payments in the U.S. 2014
- Cancer drugs on the world market 2010
- Worldwide revenue of cancer drugs
- Revenue market share of topical antifungals sold in Spain by company 2018
- Senile cataract drug sales share in South Korea 2016, by age group
- CRISPR genome editing market size projections globally 2017 vs 2024
Studies
- Oncology
- Personalized medicine
- Animal testing in the United Kingdom
- Pharmaceutical trends in Europe
- Complementary Medicines Australia 2017/18 Federal pre-Budget Submission
- Complementary Medicines Australia 2016/17 Federal pre-Budget Submission
- Complementary Medicines Australia 2015/16 Federal pre-Budget Submission
Statistics on "Oncology"
- Leading causes of death worldwide in 2016 (in millions)
- Number of cancer deaths worldwide in 2016, by major type of cancer
- Number of U.S. Americans with a history of cancer living between 2004 and 2016 (in millions)
- Number of new cancer cases in the United States from 1999 to 2015*
- Deaths by cancer in the U.S. from 1950 to 2016 (per 100,000 population)*
- Global oncology spending from 2010 to 2017 (in billion U.S. dollars)*
- Projected growth and spending in oncology market globally from 2012 to 2022 (in billion U.S. dollars)
- Global oncology therapeutic medicine spending in the period 2013-2017, by region
- Projected global oncology spending in 2022, by region (in billion U.S. dollars)
- Emerging cancer diagnostics market size worldwide in 2015 and 2023, by region (in billion U.S. dollars)
- Growth of the U.S. oncology therapeutic market from 2012 to 2017, by segment (in billion U.S. dollars)
- Top 10 pharmaceutical companies based on global oncology revenue in 2017 and 2024 (in million U.S. dollars)
- Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024
- Revenue distribution of Roche's Pharmaceuticals division in 2017 and 2018, by therapeutic area
- Revenues of biotech company Celgene's top products from 2013 to 2018 (in million U.S. dollars)
- Bristol-Myers Squibb's top products based on revenue from 2015 to 2018 (in million U.S. dollars)
- Venture investments in oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)
- Amount raised through initial public offerings (IPOs) from oncology companies in the U.S. from 2006 to 2017 (in million U.S. dollars)*
- Top 5 oncology products worldwide based on revenue in 2017 and 2024 (in million U.S. dollars)*
- Top 5 oncology products worldwide by market share in 2017 and 2024
- Availability of new cancer drugs launched in 2012-2016 in selected countries as of 2017
- Leading U.S. oncology brands based on revenue in 2016 (in million U.S. dollars)
- Number of oncology drugs by treatment cost and number of patients in the U.S. as of 2017
- Distribution of FDA breakthrough therapy requests by therapy area in 2018
- Distribution of FDA breakthrough therapy requests granted by therapy area in 2018
- Distribution of late phase oncology pipeline in 2007 and 2017, by type
- Number of cancer drugs in development in the United States in select years between 2005 and 2018
- Time between R&D start and approval of selected cancer drugs on the market as of 2017 (in years)
- Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)
- Top 10 mechanisms of action in R&D pipeline drugs worldwide by number of active compounds in 2019*
- Distribution of the immuno-oncology pipeline worldwide as of 2018, by mechanism of action
- Global cancer immunotherapy market in 2016 and projection for 2022 (in billion U.S. dollars)
- Market share forecast for top immuno-oncology companies worldwide in 2021*
- Top 10 immuno-oncology collaborations worldwide based on value as of 2018 (in billion U.S. dollars)
- Distribution of treatment types for female breast cancer in the U.S. in 2013, by stage
- Distribution of treatment types for prostate cancer in the U.S. in 2010-2012
- Distribution of treatment types for colon cancer in the U.S. in 2013, by stage
- Distribution of treatment types for lung cancer in the U.S. in 2013*
- Distribution of treatment types for non-Hodgkin lymphoma in the U.S. in 2013
- Number of oncologists per one million people in select countries as of 2018
- Number of active physicians in the U.S. in 2018, by specialty area
- Hours per week that oncologists in the U.S. spend seeing patients as of 2018
- Minutes that oncologists in the U.S. spend with each patient as of 2018
- Medication usage among patients with cancer in selected countries as of 2018*
- Lifestyle among patients with cancer in selected countries as of 2018*
- Average length of stay in U.S. hospitals per inpatient cancer cases from 2008 to 2016 (in days)
- Percentage of patients whose tumors are driven by certain genetic mutations as of 2016, by cancer type
- Revenue as a percentage of R&D spending for select cancer drugs on the market as of 2017
- Total revenue since approval for select cancer drugs on the market as of 2017 (in million U.S. dollars)
- Number of unsuccessful lung cancer drugs in the United States from 1998 to 2014
- Number of approvals for new active ingredients in cancer drugs in the U.S. from 2004 to 2013
- Number of unsuccessful melanoma drugs in development in the United States from 1998 to 2014
- Average prices of Gleevec in selected countries in 2013 (in U.S. dollars)
- Level of consumption of cancer drugs in Italy in 2017, by region (in DDD* per 1,000 inhabitants per day)
- Number of unsuccessful brain cancer drugs in development in the United States from 1998 to 2014
- Proportion of cancer drugs on the world pharmaceutical market in 2003 and 2009 (in percent)
- Number of new cancer pharmaceuticals approved by EMA (European Medicines Agency) in Sweden from 2014 to 2017
- Invoice price increases for protected oncology brands in the U.S. from 2012 to 2017
- Number of clinical trials authorized by the Italian Medicines Agency in Italy in 2017, by type of drug
- Global metastatic cancer treatment market in 2017 and 2025 (in billion U.S. dollars)
- Leading Medicare Part B cancer drugs based on average sales price per dosage in 2014 (in U.S. dollars)
- Top 10 cancer drugs based on annual Medicare Part B payments in 2014 (in million U.S. dollars)
- Proportion of cancer drugs on the world market from 2004 to 2010
- Revenue of cancer drugs worldwide in 2003 and 2009 (in billion U.S. dollars)
- Revenue market share of topical antifungals sold in Spain as of July 2018, by pharmaceutical company
- Sales distribution of the medications for senile cataract in South Korea in 2016, by age group
- Market size of CRISPR genome editing globally in 2017 and a forecast for 2024 (in million U.S. dollars)
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Please log in to access our additional functions
Register in seconds and access exclusive features.
Basic Account
|
Instant Access
Premium Account
| ||
|---|---|---|---|
Our services
Click the question mark for further information | Free |
$49 per month* | |
| Basic statistics | |||
| Premium statistics | |||
|
Graph download
| |||
| Download PDF | |||
|
Excel download
| |||
| Register | Purchase now | ||
*Duration: 12 months, billed annually, single license
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.